Abstract: According to one aspect, a method includes obtaining, at a monitoring arrangement, a first supervisory request from a first vehicle, the first supervisory request arranged to indicate that the first vehicle has identified a first potential issue. The method also includes processing, at the monitoring arrangement, the first supervisory request, wherein processing the first supervisory request includes determining whether the first potential issue is to be mitigated. When it is determined that the first potential issue is to be mitigated, information is provided from the monitoring arrangement to a control arrangement, and the control arrangement takes control of the first vehicle based on the information.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Techniques for image quality enhancement for autonomous vehicle remote operations are disclosed herein. An image processing system of an autonomous vehicle can obtain images captured by at least two different cameras and stitch the images together to create a combined image. The image processing system can apply region blurring to a portion of the combined image to create an enhanced combined image, e.g., to blur regions/objects determined to be less import (or unimportant) for the remote operations. The image processing system can encode pixel areas of the enhanced combined image using a corresponding quality setting for respective pixel areas to create encoded image files, e.g., based on complexity levels of the respective pixel areas. The image processing system can transmit the encoded image files to a remote operations system associated with the autonomous vehicle for remote operations support.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: According to one aspect, a method includes identifying, in a scene around a vehicle, at least a first object, wherein the at least first object is identified using data obtained from a sensor system of the vehicle. The method also includes determining a first type associated with the at least first object, identifying at least a first indicator associated with the first type, and providing the at least first indicator associated with the first type to a display arrangement configured to display the scene and the at least first indicator.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Abstract: Techniques for image quality enhancement for autonomous vehicle remote operations are disclosed herein. An image processing system of an autonomous vehicle can obtain images captured by at least two different cameras and stitch the images together to create a combined image. The image processing system can apply region blurring to a portion of the combined image to create an enhanced combined image, e.g., to blur regions/objects determined to be less import (or unimportant) for the remote operations. The image processing system can encode pixel areas of the enhanced combined image using a corresponding quality setting for respective pixel areas to create encoded image files, e.g., based on complexity levels of the respective pixel areas. The image processing system can transmit the encoded image files to a remote operations system associated with the autonomous vehicle for remote operations support.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Abstract: A pharmaceutical composition comprising (i) a therapeutically effective amount of an inhibitor of the oncogene SLC29A2; and (ii) a pharmaceutically acceptable carrier, for use in suppressing proliferation, occurrence, and metastasis of cancer cells overexpressing the oncogene SLC29A2 in a cancer patient, and/or prolonging cancer patient survival. The inhibitor of the oncogene SLC29A2 may be at least one selected from the group consisting of dipyridamole, dilazep, draflzine, nitorbenzylthioinosine, and the derivatives thereof. The composition for use may further comprise sorafenib for the same use.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Abstract: A pharmaceutical composition comprising (i) a therapeutically effective amount of an inhibitor of the oncogene SLC29A2; and (ii) a pharmaceutically acceptable carrier, for use in suppressing proliferation, occurrence, and metastasis of cancer cells over-expressing the oncogene SLC29A2 in a cancer patient, and/or prolonging cancer patient survival. The inhibitor of the oncogene SLC29A2 may be at least one selected from the group consisting of dipyridamole, dilazep, draflzine, nitorbenzylthioinosine, and the derivatives thereof. The composition for use may further comprise sorafenib for the same use.

Abstract: Provided are 4?-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Provided are 4?-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.